Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.36 |
| ▸ | PLAU | P00749 | 4/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582341 | 0.85 | ELANE (0.37) | ELANEPLAUF2KLKB1RECQL | |
| SCHEMBL13412138 | 0.81 | CYP4F2 (0.43) | ELANEPLAUF2KLKB1SMN1; SMN2 | |
| SCHEMBL16424171 | 0.80 | DGAT1 (0.32) | DGAT1MAPTHTTATMROCK2 | |
| SCHEMBL21995832 | 0.79 | ELANE (0.40) | ELANEPLAUF2KLKB1NPC1 | |
| SCHEMBL3766982 | 0.79 | LMNA (0.43) | ELANEPLAUF2KLKB1NPC1 | |
| SCHEMBL18622410 | 0.77 | ELANE (0.39) | ELANEPLAUF2KLKB1NPC1 | |
| SCHEMBL16423881 | 0.75 | F2 (0.40) | ELANEPLAUF2NPC1RAB9A | |
| SCHEMBL20520051 | 0.75 | ELANE (0.37) | ELANEPLAUF2KLKB1NPC1 | |
| SCHEMBL20519689 | 0.75 | MAP4K4 (0.38) | ELANEPLAUF2KLKB1NPC1 | |
| SCHEMBL2549524 | 0.75 | ELANE (0.47) | ELANEPLAUF2KLKB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | ELANE 3141/4885PLAU 2646/4885F2 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.